welcome
CNBC

CNBC

Health

Health

Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short

CNBC
Summary
Nutrition label

79% Informative

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi , saw growth.

But the biotech company's guidance for the current year missed Wall Street's expectations.

Biogen issued a full-year 2025 adjusted earnings outlook of $ 15.25 to $ 16.25 per share.

The company expects to generate $1 billion in gross savings by the end of 2025 .

VR Score

91

Informative language

98

Neutral language

53

Article tone

formal

Language

English

Language complexity

46

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links